UBS Remains Sidelined on Kindred Healthcare (KND) Ahead of 3Q Report
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
UBS maintained a Neutral rating on Kindred Healthcare (NYSE: KND), and cut the price target to $10.50 (from $12.50), ahead of the company's 3Q earnings report. The KND's model was updated to include the company's sale of 12 hospitals, as well as the purchase of the home health operations of the Arkansas Dept of Health. Q3 EPS estimates of $0.07 compares with the company's quarterly guidance of $0.02-0.12.
Analyst A.J. Rice commented, "We are updating our model to include the impact of KND's sale of 12 hospitals (closed early Oct), as well as the purchase of the home health operations of the Arkansas Dept of Health (closed Aug 1). On Oct 3, KND sold 12 LTACHs to Curahealth for cash proceeds of $21 mln (plus contingent consideration). The 12 hospitals were expected to generate revs of $215 mln, EBITDAR of $14 mln, and breakeven EBITDA in 2016. KND has noted in the past that trimming its LTAC footprint will allow it to focus on being efficient in its remaining markets. Also included in our updated model is the purchase of the home health operations of the Arkansas Dept of Health (closed Aug 1). The HH acquisition, which cost the company $39 mln, should provide $40 mln annual revenues. We are lowering our 2016 and 2017 revenue estimates by $48/$155 mln to $7,205/$7,237 mln, respectively. We are reducing our 2016 and 2017 EBITDAR estimates by $3/$9 mln to $982/$991 mln, respectively. However, given the EBITDA neutral impact of the sale of 12 hospitals and modestly accretive expectation for Arkansas home health, we are increasing our 2017 EPS estimates by $0.02 to $0.92. Neither of these two transactions is included in the company's current guidance."
Shares of Kindred Healthcare closed at $9.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Cuts Price Target on Restoration Hardware (RH) to $34 Following 3Q
- MKM Partners Raises Price Target on Finisar (FNSR) to $43 Following 2Q
- Jefferies Raises Price Target on Broadcom Ltd. (AVGO) to $210 Following 4Q
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesUBS, Earnings, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!